Midterm Results of the Supera Stent for the Treatment of Femoropopliteal Occlusive Disease

• Published in: Annals of vascular surgery Vol. 86; pp. 177 - 183
• Main Authors: Low, Josiah, Shih, Terri, Lu, Eileen, Derubertis, Brian G., Baril, Donald T.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-10-2022
• ISSN: 0890-5096; 1615-5947
• DOI: 10.1016/j.avsg.2022.05.031

The Supera (Abbott Vascular, Santa Clara, CA) stent is an interwoven nitinol, shape-memory stent with high strength and flexibility characteristics which are purported to increase resistance to kinking and compression. The purpose of this study was to review single-center outcomes of the use of this stent in the femoropopliteal segment.
We performed a single-center, retrospective analysis of patients who underwent Supera stent placement for femoropopliteal occlusive disease from 2016–2019. Data was collected on patient demographics and procedural details. Follow-up imaging data, including duplex imaging and ankle-brachial indices, and clinical data were abstracted from encounter notes.
Sixty-two patients with 72 unique Supera stent placements were identified. Mean age was 76 and 69% were male. 56% of patients had severe calcification and 11% had moderate calcification. 48% of lesions were Trans-Atlantic Inter-Society Consensus Document C or D lesions. Primary patency rates at 12, 24, and 36 months were 85%, 82%, and 75%, respectively. Primary patency was not affected significantly by lesion length, degree of calcification, number of outflow vessels, concomitant interventions, or stent size.
These results demonstrate sustained primary patency with the Supera stent over a 3-year interval in treatment of patients with femoropopliteal occlusive disease, including in the setting of severely calcified vessels.